HIV triple therapy tablet containing new version of tenofovir

Odefsey (rilpivirine/emtricitabine/tenofovir alafenamide) is indicated in the treatment of patients aged 12 years and over and weighing at least 35kg who are infected with HIV-1 without known mutations associated with resistance to NNRTIs, tenofovir or emtricitabine and who have a viral load ≤100,000 HIV-1 RNA copies/ml. The 25mg/200mg/25mg tablet should be taken once daily with food.

Further information
View Odefsey drug record
Summary of Product Characteristics
Manufacturer: Gilead Sciences

Gilead also markets Eviplera, a similar product containing rilpivirine 25mg and emtricitabine 200mg but with a different tenofovir salt (tenofovir disoproxil 245mg).

Tenofovir alafenamide is a novel targeted prodrug of tenofovir which has high antiviral efficacy similar to tenofovir disoproxil but at a significantly lower dose (25mg versus 245mg).

As a result, Odefsey may be used in patients with moderate renal impairment (CrCl ≥30ml/min) while Eviplera is contraindicated if creatinine clearance is below 50ml/min. In addition, Eviplera is associated with a risk of reduced bone mineral density, especially when used in combination with a boosted protease inhibitor and alternative regimens should be considered in patients with osteoporosis and a high fracture risk. No such warning applies to the use of Odefsey.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases